S
SiteOne Therapeutics
Developing novel therapeutics focused on the peripheral nervous system,
About SiteOne Therapeutics
SiteOne Therapeutics, Inc. is a biopharmaceutical firm established in 2011, focusing on the development of non-opioid pain relief medications. The company was co-founded by George Miljanich and John Hunter, who both possess extensive experience in the field of neuroscience and ion channel modulation from their time at Elan Pharmaceuticals. Their work is rooted in over three decades of research into the biology and structure of the Nav1.7 sodium ion channel, a genetically validated target for pain signals.
The company's primary business involves discovering and advancing a new class of highly selective sodium ion channel (Nav) inhibitors. By targeting Nav1.7, SiteOne aims to stop the transmission of pain signals at their source without the central nervous system side effects and addictive potential associated with opioids. This positions the company within the specialty pharmaceutical market, specifically addressing the significant unmet need for safer and more effective analgesics for conditions like acute, chronic, and neuropathic pain. The business model is typical of a clinical-stage biopharmaceutical company, revolving around research and development, securing intellectual property, and progressing drug candidates through the FDA's clinical trial phases, with revenue generation likely tied to partnerships, licensing deals, or eventual commercialization of an approved drug.
SiteOne's lead product candidates are ST-2427 and ST-2645, which are being investigated for treating moderate-to-severe pain. ST-2427, an oral medication, has successfully completed Phase 1 clinical trials, demonstrating a favorable safety and tolerability profile. The development of these candidates is supported by a robust intellectual property portfolio. A significant milestone was achieved in 2024 when the company secured an oversubscribed $45 million Series D financing round, co-led by Braidwell LP and existing investor TPG's The Rise Fund. This funding is intended to advance ST-2427 through Phase 2 clinical trials for multiple pain indications.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Employees
- 3
- Open positions
- None listed
- Dealroom signal
- 28.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Verified Unicorns and $1B Exits, Biotech and Pharma, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Marketplace & ecommerce
- Client focus
- B2C
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | May 2025 | $1B | $1B | Eli Lilly | ↗ |
| SERIES COther financing | Dec 2024 | $100M | $400M | OrbiMed · Mission BioCapital · BSQUARED Capital · Wellington Management | ↗ |
Growth signals
Latest recorded traffic for SiteOne Therapeutics is 0 monthly website visits. SiteOne Therapeutics's team declined 25% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
SiteOne Therapeutics in the San Francisco ecosystem
The SiteOne Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
- SMSears Capital Management
Bay Capital- BIBioBrit
Mission Bay Capital
NEXT Frontier Capital
Amgen
Series B and later5 investors entered at this stage
Novo Holdings
OrbiMed
Mission BioCapital
BSQUARED Capital
Wellington Management
Other known investors1 additional known investor
Eli Lilly
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about SiteOne Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See SiteOne Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








